Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
GlaxoSmithKline plc GSK, one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Additionally, the companies created a joint venture (JV), thereby combining their consumer divisions to form a larger consumer health care business.
Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).
However, like many of its peers, Glaxo is facing challenges in the form of stiff competition, genericization, pricing pressure and slowing growth in emerging markets. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been pretty good so far, with the company’s earnings beating expectations thrice in the trailing four quarters while missed in another. Overall, the company has delivered an average positive surprise of 1.41%.
Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Glaxo reported core earnings of 92 cents per American depositary share in the third quarter of 2018, which beat our consensus estimate of 86 cents. The company’s focus on cost control initiative has boosted margins.
Revenues In-line: Revenues were up 6% year over year at constant exchange rate (CER) to $10.55 billion (£8.1 billion). Revenues met Zacks Consensus Estimate.
Key Stats:While sales in Consumer Healthcare and Pharmaceuticals were up 3%, the Vaccines segment increased 17% at CER.
2018 Guidance: Glaxo expects EPS growth of 8-10% at CER in 2018 irrespective of launch of Advair generic. The company increased expectation for Shingrix sales to the range of £700-750 million.
Share Price Impact: Shares rose almost 2.2% in pre-market trading.
Check back later for our full write up on GSK earnings report later!
GlaxoSmithKline plc Price and EPS Surprise
GlaxoSmithKline plc Price and EPS Surprise | GlaxoSmithKline plc Quote
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
